CoChat

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

Open access
Popoviciu, Mihaela-Simona, Păduraru, Lorena, Yahya, Galal, Metwally, Kamel, Cavalu, Simona · 2023 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 141 of the 145 references it cites were found in a registry or an index.

Abstract

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms241310449

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The worldwide prevalence of obesity in 2025: (a) females and (b) males. Obesity refers to BMI ≥ 30 kg/m2. Age-standardized estimates for adults aged 20 years and older. Data obtained from NCD-RisC study. Available online: https://www.ncdrisc.org (accessed on 15 February 2023).
Figure 1 The worldwide prevalence of obesity in 2025: (a) females and (b) males. Obesity refers to BMI ≥ 30 kg/m2. Age-standardized estimates for adults aged 20 years and older. Data obtained from NCD-RisC study. Available online: https://www.ncdrisc.org (accessed on 15 February 2023).CC BY · PubMed Central
Figure 2 Complications of obesity.
Figure 2 Complications of obesity.CC BY · PubMed Central
Figure 3 The structure of GLP-1-parent.
Figure 3 The structure of GLP-1-parent.CC BY · PubMed Central
Figure 4 Development of exenatide and the corresponding chemical structure.
Figure 4 Development of exenatide and the corresponding chemical structure.CC BY · PubMed Central
Figure 5 Development of Lixisenatide and the corresponding chemical structure.
Figure 5 Development of Lixisenatide and the corresponding chemical structure.CC BY · PubMed Central
Figure 6 Development of liraglutide and the corresponding chemical structure.
Figure 6 Development of liraglutide and the corresponding chemical structure.CC BY · PubMed Central
Figure 7 Development of semaglutide and the corresponding chemical structure.
Figure 7 Development of semaglutide and the corresponding chemical structure.CC BY · PubMed Central
Figure 8 Development of tirzepatide and the corresponding chemical structure.
Figure 8 Development of tirzepatide and the corresponding chemical structure.CC BY · PubMed Central
Figure 9 Development of albiglutide and the corresponding chemical structure.
Figure 9 Development of albiglutide and the corresponding chemical structure.CC BY · PubMed Central
Figure 10 Distribution of GLP-1 receptors. GLP-1Rs (pdb6X18) mainly exist in the neurons of the brain and the beta cells of the pancreas.
Figure 10 Distribution of GLP-1 receptors. GLP-1Rs (pdb6X18) mainly exist in the neurons of the brain and the beta cells of the pancreas.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Research works printed but not linked: 3

  1. 2006, Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug, J. Appl. Sci. Res., 2, 205
  2. Kanwal, 2021, Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review, Middle East J. Fam. Med., 19, 72
  3. (2019). Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet], Canadian Agency for Drugs and Technologies in Health.

Cited by

See all 294

Metadata

Authors
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S.
Affiliations
  • University of Oradea (RO)
  • University of Kaiserslautern (DE)
  • Zagazig University (EG)
Corresponding author
Cavalu, Simona
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-06-21
Volume
24
Issue
13
Pages
10449
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4381618228
Cited by
280
References
145
Citations by year
2026: 70 · 2025: 131 · 2024: 67 · 2023: 12
FWCI
10.17
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
University of Oradea
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity, weight loss, type 2 diabetes, hyperglycemia, insulin sensitivity, blood pressure, cardioprotection, renal protection, obesity-related comorbidities, long-term safety, non-diabetic patients
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Weight Loss, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. https://app.cochat.ai/papers/10.3390/ijms241310449
The paper
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023). Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.